CHRO vs. TCON, PALI, FRTX, ALBT, KRBP, TTNP, CELZ, ELOX, GMDAQ, and GMDA
Should you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include TRACON Pharmaceuticals (TCON), Palisade Bio (PALI), Fresh Tracks Therapeutics (FRTX), Avalon GloboCare (ALBT), Kiromic BioPharma (KRBP), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDAQ), and Gamida Cell (GMDA). These companies are all part of the "biological products, except diagnostic" industry.
TRACON Pharmaceuticals (NASDAQ:TCON) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability.
11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Chromocell Therapeutics has lower revenue, but higher earnings than TRACON Pharmaceuticals.
TRACON Pharmaceuticals' return on equity of 0.00% beat Chromocell Therapeutics' return on equity.
TRACON Pharmaceuticals currently has a consensus target price of $60.00, suggesting a potential upside of 3,214.92%. Given Chromocell Therapeutics' higher possible upside, equities analysts clearly believe TRACON Pharmaceuticals is more favorable than Chromocell Therapeutics.
TRACON Pharmaceuticals received 265 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
In the previous week, TRACON Pharmaceuticals had 2 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 2 mentions for TRACON Pharmaceuticals and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.50 beat TRACON Pharmaceuticals' score of 0.00 indicating that TRACON Pharmaceuticals is being referred to more favorably in the media.
Summary
TRACON Pharmaceuticals beats Chromocell Therapeutics on 8 of the 10 factors compared between the two stocks.
Get Chromocell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chromocell Therapeutics Competitors List
Related Companies and Tools
